Previous 10 | Next 10 |
Despite recent regulatory hurdles, the U.S.-listed Chinese pharmaceutical companies have made a comeback in the morning hours on Wednesday. Notable gainers include I-Mab (IMAB +17.9%), BeiGene (BGNE +20.8%), Legend Biotech (LEGN +9.3%), Zai Lab (ZLAB +30.4%), HUTCHMED < > Limited (HCM...
KE Holdings (NYSE:BEKE) +47%. DiDi Global (NYSE:DIDI) +44%. Pinduoduo (NASDAQ:PDD)+35% Alibaba, other Chinese tech stocks soar as government says it will support market. Dingdong (Cayman) (NYSE:DDL) +35%. Kingsoft Cloud (NASDAQ:KC) +32%. Zhihu (NYSE:ZH) +31%. ATRenew (NYSE:RERE) +3...
I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act PR Newswire SHANGHAI and GAITHERSBURG, Md. , March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to th...
Gainers: Zhongchao (NASDAQ:ZCMD) +35%. Moderna (NASDAQ:MRNA) +15%. ERYTECH Pharma (NASDAQ:ERYP) +14%. Allied Healthcare Products (NASDAQ:AHPI) +13%. 4D pharma (NASDAQ:LBPS) +13%. Losers: Nektar Therapeutics (NASDAQ:NKTR) -53%. MultiPlan (NYSE:MPLN) -26%. ...
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting PR Newswire SHANGHAI and GAITHERSBURG, Md. , March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceuti...
Gainers: Voyager Therapeutics (NASDAQ:VYGR) +22%. 908 Devices (NASDAQ:MASS) +16%. Viemed Healthcare (NASDAQ:VMD) +10%. Cara Therapeutics (NASDAQ:CARA) +9%. Neuronetics (NASDAQ:STIM) +9%. Losers: Alector (NASDAQ:ALEC) -19%. Can-Fite BioPharma (NYSE:CANF)...
The U.S. Food and Drug Administration granted orphan drug designation to I-Mab's (IMAB -8.1%) TJ-CD4B to treat gastric cancer including cancer of gastroesophageal junction. TJ-CD4B is part of I-Mab's bispecific antibody pipeline. The therapy is currently undergoing phase 1 tria...
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer PR Newswire SHANGHAI and GAITHERSBURG, Md. , March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a cl...
Gainers: Brookdale Senior Living BKD +16%. American Shared Hospital Services AMS +12%. ImmunityBio IBRX +12%. I-Mab (NASDAQ:IMAB) +11%. Corvus Pharmaceuticals (NASDAQ:CRVS) +9%. Losers: Larimar Therapeutics LRMR -65%. Omnicell (NASDAQ:OMCL) -18%. M...
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs PR Newswire SHANGHAI and GAITHERSBURG, Md. , Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage bi...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...